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ABSTRACT 
 A new simple, accurate ,precise and reproducible RP-HPLC method has been developed for 
simultaneous estimation of metformin and pioglitazone in bulk drug form using proper HPLC 
system. The mobile phase consists of phosphate buffer and acetonitrile in the ratio of 35:65 at 
pH 3.4.The detection wavelength was carried out at 228 nm. The method was linear over the 
concentration range for metformin 50-100 μg/mL and for pioglitazone 20-180 μg/mL. The 
recoveries of metformin and pioglitazone were found to be 100.5 and 98.7% respectively. The 
validation of method was carried out utilizing ICH-guidelines. The described HPLC method 
method was successfully for the analysis of pharmaceutical formulations containing dosage 
form. 
Introduction
Metformin is chemically N,N-Dimethylimidodicarbonimidic 
diamide drug with chemical formula C4H11N5  and molecular 
weight 129.16364 g/mol.Metformin and pioglitazone
 
are used 
as anti diabetic agent[1-3].The structural formula is: 
 
(A) 
 
(B) 
Fig 1: structure of metformin(A) and pioglitazone (B) 
 
It has been used in conjuction with exercise and diet to 
improve diabetic condition and normal glucose level. 
Pioglitazone is chemically (RS)-5-(4-[2-(5-ethylpyridin-2-
yl)ethoxy]benzyl)thiazolidine-2,4-dione with molecular 
formula C19H20N2O3S and molecular weight is 356.44 g/mol . 
It is used for the treatment of diabetic patient. The method is 
developed by rp hplc
4
 and different validation parameter 
[5,6]are developed with the help of HPLC[7-12] and UV 
visible instrument. 
Experimental 
Apparatus and reagent 
 
The liquid chromatographic system consists of shimadzu with 
uv-vis detector, pump and injector valve with 20 micro litre 
fixed loop. The analytes were monitored at 228 nm. All 
chemicals and reagents were used AR grade. The metformin 
and pioglitazone were obtained as gift sample from Cipla. 
 
Selection of detection wavelength 
 
Selection of drug were scanned over the range of 200- 400 
nm. It was observed that the drugs showed considerable 
absorbance at λmax at 205 nm and 270 nm for metformin and 
pioglitazone respectively. The isobetic point of both drugs was 
found to be 228 nm. 
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Fig 2: Isobetic point of metformin and pioglitazone 
 
Chromatographic condition 
 
The column is calibrated and equilibrated with mobile phase 
acetonitrile and phosphate buffer 65:35 at pH 3.4. The flow 
rate was maintained at 1.5 ml/min, detection wavelength 228 
nm and the injection volume was 20 micro litre and 
temperature 25˚C. 
 
Preparation of standard and sample solution 
The standard stock solution of metformin was prepared by 
dissolving 200 mg metformin in100 ml of diluent to get a 
solution containing 2mg/ml of metformin. The standard stock 
solution of pioglitazone was prepared by dissolving 10 mg 
pioglitazone in 100 ml of diluent to get a solution containing 
100 µg /ml of pioglitazone. Working standard solution of 
metformin was prepared by diluting appropriate aliquot of 
stock solution with diluent to get a solution containing 50 
µg/ml metformin. Working standard solution of pioglitazone 
was prepared by diluting appropriate aliquot of standard stock 
solution of pioglitazone with diluents to get a solution 
containing 200µg/ml of pioglitazone. Twenty tablets (each 
tablet containing metformin 500 mg and pioglitazone 15 mg 
were accurately weighed, their mean weight was determined 
and the tablets were powdered in a glass mortar. An amount of 
powder equivalent to two tablets was dissolved in 50 mL of 
diluent and was sonicated for 20 min. The resulting mixture 
was filtered through 0.45μ membrane filter (SY25TG,mdi 
Membrane Technologies, California USA).The filtrate ,thus 
obtained containing metformin equivalent to 50 µg/mL and 
pioglitazone  equivalent to 200 μg/mL was used for analysis. 
Method Development 
Lots of mobile phase and there different conc. We tried and 
finally selected acetonitrile and phosphate buffer in ratio 65:35 
at pH 3.4 approx. Mobile phase which gave good resolution 
and acceptable system suitability parameter. The 
chromatogram of working std. soln. is shown in fig 3. 
 
Fig 3: HPLC chromatogram of metformin and pioglitazone 
Analytical validation parameter 
Linearity: A good linear relationship between concentration 
and peak areas over a concentration range of 50-100µg/ml for 
metformin and 20-180 µg/ml for pioglitazone. The correlation 
coefficient was found to be 0.999 for metformin and 0.999 for 
pioglitazone which are greater than 0.999.  
Accuracy: Percent recoveries were obtained from the 
difference between the areas of spiked and unspiked samples. 
The mean recovery of the added standard drug was 100.5 and 
98.70% for metformin and pioglitazone respectively. These 
mean recovery values are well within the 98-102% indicating 
the method is accurate. 
 
Precision: RSD of mean assay values was found to be 0.28% 
for metformin and 1.02% for pioglitazone. These %RSD 
values which are well below 2% indicate that the repeatability 
of this method is satisfactory. 
LOD AND LOQ: The LOD was found to be 1.52 µg/mL for 
metformin and 20.2 µg/mL for pioglitazone. LOQ was found 
to be 12.4 µg/mL for metformin and 13.5 µg/mL for 
pioglitazone. These values indicate that the method is 
sensitive. 
Specificity: Good resolution was obtained between the drugs 
and excipients showing complete sepration of metformin and 
pioglitazone. No interference from excipients, impurities, or 
degradation products ensured that the peak response was due 
to metformin and pioglitazone only. 
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Analytical parameter 
 
Parameter Metformin Pioglitazone 
Linearity range(µg/ml) 50-100 20-180 
Retention time 2.4 5.2 
Accuracy( % recovery) 100.5 98.7 
Precision repeatability(%RSD) 0.20 1.02 
LOD (µg/ml) 1.52 1.02 
LOQ (µg/ml) 1.24 1.35 
Precision intermediate(%RSD) 1.71 1.82 
 
Results and discussion 
The present work done on this combination comprises a 
simple and accurate method by reverse phase hplc. An attempt 
has been made to estimate metformin and pioglitazone by rp-
hplc. Caliberation curve depiciting the linearity and range for 
metformin and pioglitazone were determine from mixed std. 
and were found to be order 50-100 and 20-180 respectively. 
The retention time for metformin and pioglitazone were 2.4 
and 5.2 respectively. The results obtained from hplc method 
were reproducible and encouraging. The values % was within 
limit(>2%) and recover close to 100% indicating reproducible 
and accuracy of method. 
Conclusion 
Proposed study describes method for the estimation of 
metformin and pioglitazone combination in mixture. The 
method was validated and found to be simple, accurate and 
precise as per ICH guidelines. The method was successful 
used for determination of drugs in their pharmaceutical 
formulation. 
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